TapewireFind a company

person · Reporting owner

Michelon Francois Roger

Disclosed activity across 1 company

Tapewire entity
117424
SEC CIK
0001691470

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ENDRA Life Sciences Inc.NDRA · Entity 8083Director · Chief Executive OfficerJanuary 30, 2023February 01, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ENDRA Life Sciences Inc.

Report date January 30, 2023 · Filed February 01, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.02 · Expires 2033-01-30Direct69,531 Reported balance After 2023-01-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-01-30 · Grant · Acquired 69,531 · Balance 69,531

F1: This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 30, 2023 Filed Feb 1, 2023 20:30 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantStock Options · Derivative 69,531 $0.00 Strike: $4.02 $0.00
Disclosure

SEC source: 0001209191-23-006046 · doc4.xml · derivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,531

Underlying: Common Stock · 69,531 shares

Expires 2033-01-30

F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.

Read SEC document
May 17, 2022 Filed May 19, 2022 07:00 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 PurchaseCommon Stock 5,100 $0.19 $969.00
Disclosure

SEC source: 0001209191-22-030307 · doc4.xml · nonDerivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,191

Read SEC document
March 28, 2022 Filed Mar 30, 2022 17:15 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantStock Options · Derivative 713,132 $0.00 Strike: $0.38 $0.00
Disclosure

SEC source: 0001209191-22-021622 · doc4.xml · derivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 713,132

Underlying: Common Stock · 713,132 shares

Expires 2032-03-28

F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.

Read SEC document
April 05, 2021 Filed Apr 7, 2021 16:05 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantStock Options · Derivative 50,000 $0.00 Strike: $2.64 $0.00
Disclosure

SEC source: 0001209191-21-025842 · doc4.xml · derivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2031-04-05

F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022.

Read SEC document
December 04, 2020 Filed Dec 8, 2020 07:04 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 SaleCommon Stock 71,519 $0.83 $59,360.77
Disclosure

SEC source: 0001209191-20-062113 · doc4.xml · nonDerivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,091

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes unvested restricted stock units.

Read SEC document
June 23, 2020 Filed Jun 24, 2020 08:21 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 OtherWarrants · Derivative 2,874 $0.00 Strike: $0.87 $0.00
Disclosure

SEC source: 0001209191-20-038680 · doc4.xml · derivative · entry 2

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,152

Underlying: Common Stock · 2,874 shares

Expires 2024-12-11

Read SEC document
June 23, 2020 Filed Jun 24, 2020 08:21 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 OtherCommon Stock 2,874 $0.87 $2,500.38
Disclosure

SEC source: 0001209191-20-038680 · doc4.xml · nonDerivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,610

F1 · balance_after: Includes unvested restricted stock units.

Read SEC document
June 08, 2020 Filed Jun 10, 2020 07:36 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 ConversionSeries A Convertible Preferred Stock · Derivative 4.372 $1,143.68 Strike: $0.87 $5,000.17
Disclosure

SEC source: 0001209191-20-035436 · doc4.xml · derivative · entry 2

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,175 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87.

F3 · derivative.expiration_date: The Series A Convertible Preferred Stock has no expiration date.

Read SEC document
June 08, 2020 Filed Jun 10, 2020 07:36 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 ConversionCommon Stock 5,175 $0.87 $4,502.25
Disclosure

SEC source: 0001209191-20-035436 · doc4.xml · nonDerivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,736

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes unvested restricted stock units.

Read SEC document
April 09, 2020 Filed Apr 13, 2020 16:35 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantCommon Stock 123,064 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-024209 · doc4.xml · nonDerivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,561

F1 · shares: Represents restricted stock units granted in lieu of a portion of the Reporting Person's cash salary. Subject to continued employment, the restricted stock units vest each day, pro rata based on the number of days between the grant date and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes unvested restricted stock units.

Read SEC document
December 11, 2019 Filed Dec 11, 2019 17:51 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantWarrants · Derivative 5,026 Not disclosed Strike: $0.87 Not disclosed
Disclosure

SEC source: 0001209191-19-060089 · doc4.xml · derivative · entry 3

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,026

Underlying: Common Stock · 5,026 shares

Expires 2024-12-11

F4 · price: The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock.

Read SEC document
December 11, 2019 Filed Dec 11, 2019 17:51 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantSeries A Convertible Preferred Stock · Derivative 4.372 $1,143.68 Strike: $0.87 $5,000.17
Disclosure

SEC source: 0001209191-19-060089 · doc4.xml · derivative · entry 2

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4.372

Underlying: Common Stock · 5,026 shares

Expires not disclosed

F2 · derivative.exercise_price: The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87.

F3 · derivative.expiration_date: The Series A preferred stock has no expiration date.

Read SEC document
December 11, 2019 Filed Dec 11, 2019 17:51 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantStock option (right to buy) · Derivative 611,994 $0.00 Strike: $0.90 $0.00
Disclosure

SEC source: 0001209191-19-060089 · doc4.xml · derivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 611,994

Underlying: Common Stock · 611,994 shares

Expires 2029-12-11

F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date.

Read SEC document
December 13, 2018 Filed Dec 17, 2018 16:36 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantStock Options · Derivative 125,000 $0.00 Strike: $2.25 $0.00
Disclosure

SEC source: 0001209191-18-062948 · doc4.xml · derivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2026-12-13

F1 · derivative.exercise_date: These Stock Options become exercisable in three equal annual installments beginning on December 13, 2019.

Read SEC document
November 13, 2018 Filed Nov 15, 2018 16:17 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 ConversionConvertible Promissory Note · Derivative Not disclosed $10,000.00 Strike: $1.68 $10,000.00
Disclosure

SEC source: 0001209191-18-058719 · doc4.xml · derivative · entry 2

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 5,953 shares

Expires 2018-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Pursuant to the terms of the Convertible Promissory Note (the "Note"), the principal amount of the Note automatically converted into shares of the Issuer's Common Stock upon the consummation of a Qualified Financing (as defined in the Note) at the lowest per share price at which Common Stock was sold by the Issuer in the Qualified Financing, less a discount of 20%.

Read SEC document
November 13, 2018 Filed Nov 15, 2018 16:17 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 ConversionCommon Stock 5,953 $1.68 $10,001.04
Disclosure

SEC source: 0001209191-18-058719 · doc4.xml · nonDerivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,497

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note described in footnote (2).

Read SEC document
June 28, 2018 Filed Jul 2, 2018 19:33 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantWarrants · Derivative 2,480 $0.00 Strike: $2.52 $0.00
Disclosure

SEC source: 0001209191-18-040507 · doc4.xml · derivative · entry 2

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,480

Underlying: Common Stock · 2,480 shares

Expires 2021-06-28

F4 · price: The Warrants were issued for no additional consideration in connection with the offer and sale of the Note.

Read SEC document
June 28, 2018 Filed Jul 2, 2018 19:33 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantConvertible Promissory Note · Derivative Not disclosed $10,000.00 $10,000.00
Disclosure

SEC source: 0001209191-18-040507 · doc4.xml · derivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 4,961 shares

Expires 2018-12-31

F1 · derivative.exercise_price: The Convertible Promissory Note (the "Note") is convertible into the Issuer's common stock at a conversion price equal to the lesser of (a) the lowest per share price at which common stock is sold by the Issuer in a sale resulting in aggregate gross cash proceeds of at least $7.0 million (a "Qualified Financing"), less a discount of 20%, or (b) $2.016, but in any event no less than a conversion price floor of $1.40, which conversion price is subject to adjustment in certain circumstances in accordance with the terms of the Note.

F2 · derivative.exercise_date: The principal amount of the Note will automatically convert into shares of the Issuer's common stock (i) upon the consummation of a Qualified Financing or (ii) if the holders of a majority of the aggregate principal amount of outstanding Convertible Promissory Notes elect to convert such notes at any time until three days prior to a Qualified Financing. Additionally, the reporting person is entitled to convert the principal amount of the Note into common stock (i) at any time until three days prior to the consummation of a Qualified Financing or (ii) if a material Event of Default (as defined in the Note) shall have occurred and be continuing. In each case, conversion is subject to the terms and provisions of the Note.

F3 · derivative.underlying_shares: The number of shares of common stock shown in Column 7 assumes a conversion price of $2.016, which is subject to adjustment in certain circumstances (see Footnote 1).

Read SEC document
June 09, 2017 Filed Jun 13, 2017 16:43 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantStock Options · Derivative 31,960 $0.00 Strike: $4.55 $0.00
Disclosure

SEC source: 0001209191-17-039505 · doc4.xml · derivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,960

Underlying: Common Stock · 31,960 shares

Expires 2022-05-12

F1 · derivative.exercise_date: These Stock Options become exercisable in three equal annual installments beginning on May 12, 2018.

Read SEC document
June 09, 2017 Filed Jun 28, 2017 16:14 UTC Amendment ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantStock Options · Derivative 31,960 $0.00 Strike: $4.55 $0.00
Disclosure

SEC source: 0001209191-17-042112 · doc4a.xml · derivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,960

Underlying: Common Stock · 31,960 shares

Expires 2025-05-12

F1 · derivative.exercise_date: These Stock Options become exercisable in three equal annual installments beginning on May 12, 2018.

F2 · derivative.expiration_date: This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The correct expiration date is May 12, 2025.

Read SEC document
May 12, 2017 Filed May 16, 2017 21:13 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantStock Options · Derivative 307,310 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001209191-17-032894 · doc4.xml · derivative · entry 3

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,310

Underlying: Common Stock · 307,310 shares

Expires 2022-05-12

F3 · derivative.exercise_date: These Stock Options become exercisable in three equal annual installments beginning on May 12, 2018.

Read SEC document
May 12, 2017 Filed May 16, 2017 21:13 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 ConversionConvertible Promissory Note · Derivative Not disclosed $0.00 Strike: $1.40 $37,163.00
Disclosure

SEC source: 0001209191-17-032894 · doc4.xml · derivative · entry 2

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2017-05-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The principal amount of, and accrued interest on, the Convertible Promissory Note converted into shares of Common Stock of the Issuer at a conversion price of $1.40 per share immediately prior to the consummation of the Issuer's initial public offering.

Read SEC document
May 12, 2017 Filed May 16, 2017 21:13 UTC ENDRA Life Sciences Inc. NDRA · Entity 8083 ConversionCommon Stock 26,544 $1.40 $37,161.60
Disclosure

SEC source: 0001209191-17-032894 · doc4.xml · nonDerivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,544

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note, as described in footnote (2).

Read SEC document
May 12, 2017 Filed May 23, 2017 18:00 UTC Amendment ENDRA Life Sciences Inc. NDRA · Entity 8083 GrantStock Options · Derivative 307,310 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001209191-17-034730 · doc4a.xml · derivative · entry 1

Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,310

Underlying: Common Stock · 307,310 shares

Expires 2025-05-12

F1 · derivative.exercise_date: These Stock Options become exercisable in three equal annual installments beginning on May 12, 2018.

F2 · derivative.expiration_date: This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The correct expiration date is May 12, 2025.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.